NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an antagonist of the AMPA receptor. NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks …

We found that only NBQX had an effect on acute seizure development, resulting in a significantly higher number of mice experiencing seizures, an increase in the number of seizures per …

NBQX is a compound that shows a 30-fold greater affinity for AMPA binding compared to kainate binding, and is essentially inactive at the glycine site of the NMDA receptor. You might find …

DNQX is known to block the effect of agonists by competing for the same site on the receptor. When applied to rat hippocampal neurons in culture, DNQX produces a dose-dependent …

The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacology. …

Jun 1, 2016 · NBQX is a highly selective competitive antagonist of AMPA/KA glutamate receptors. NBQX had an effect on acute seizure development in the virus-induced seizure model. NBQX …

Feb 2, 1990 · NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine sites. NBQX protects against …

Oct 10, 2018 · The selective AMPA antagonist NBQX produced significant suppression of all forms of social behavior in adolescents and adults, with no socially facilitating effects evident …